CND Life Sciences, a leading medical technology company specializing in neurodiagnostic tests, has announced a groundbreaking publication in the Journal of the American Medical Association (JAMA) detailing the efficacy of their Syn-One Test. The test, which utilizes a simple skin biopsy procedure, has proven remarkably effective in detecting phosphorylated alpha-synuclein (P-SYN), a key biomarker for synucleinopathies, in most patients.
The pivotal peer-reviewed study, “Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients with Synucleinopathies,” involved a cross-sectional analysis of 428 patients across 30 sites. Those studied included individuals with clinically diagnosed Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF), alongside healthy subjects for comparison. The research supported by the National Institutes of Health (NIH) demonstrated detection rates of P-SYN in patients ranging from 92.7% in PD cases to 100% in PAF cases, with a notably low positivity rate of 3.3% among healthy subjects.
This discovery holds immense promise for neurodegeneration, particularly in improving diagnostic accuracy for PD, MSA, DLB, and PAF conditions. Misdiagnosis of these diseases, especially in their early stages, has been a pervasive challenge, further compounded by limited access to specialized neurological care. With over 30% of synucleinopathy cases potentially misclassified, mainly in early disease phases, the Syn-One Test offers a much-needed solution to accurately identifying these conditions, significantly benefiting clinical practice and drug development efforts.
The Syn-One Test serves as a vital tool for precise diagnosis and a quantifiable biomarker that can inform disease severity and progression assessments. This development is poised to revolutionize patient care by ensuring more timely and accurate diagnoses and advancing targeted therapies. As the neurodegeneration field moves towards precision diagnostics and treatments, tools like the Syn-One Test are instrumental in realizing these advancements, promising a brighter future for patients and families affected by these debilitating disorders.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
